Molina Healthcare will exit its traditional, non-dual Medicare Advantage prescription drug plans after December 31, 2026, a decision CEO Joe Zubretsky announced on the company's February 5, 2026 fourth-quarter earnings call as a shift to focus exclusively on dual eligible members in Medicare. The exiting MAPD contracts covered approximately 117,000 members in 2025, with enrollment expected to fall to about 80,000 during 2026, and the product was expected to produce approximately $1 billion in 2026 premium revenue. Molina is staying in Medicare and keeping its $5 billion dual-eligible Medicare business, and continues to pursue new Duals contracts in Idaho, Illinois, Massachusetts, Michigan, and Ohio. The formal member nonrenewal letter, governed by the CMS calendar, does not go out until early October, leaving affected members roughly eight weeks to act before the December 7 end of the Annual Enrollment Period. Members who do nothing risk returning to Original Medicare on January 1 without prescription coverage, and going 63 straight days without Part D or other creditable drug coverage can trigger a late-enrollment penalty starting January 1, 2027.
Molina Healthcare IncMolina will exit its traditional non-dual Medicare Advantage prescription drug plans after 2026, dropping ~117,000 members and ~$1B in 2026 premium revenue under the CMS-governed nonrenewal process.
